Clinical trials will be conducted by the NIA’s nationwide consortium.
The Alzheimer’s Disease Cooperative Study, a federally established consortium conducting clinical trials on Alzheimer’s Disease (AD), will receive $52 million over six years to conduct several new trials.

The award will help test drugs for their effectiveness in slowing down the progression or treating the symptoms of AD, as well as to investigate new methods for conducting dementia research. Specifically, researchers will focus on possible therapies aimed at affecting the beta amyloid peptide and the tau protein, both of which are involved in the development of AD.

The award is a cooperative agreement between the National Institute on Aging’s (NIA) and the University of California, San Diego (UCSD), which coordinates the consortium of nearly 70 sites in the U.S. and Canada.

Previous articleSantarus Hands Over OTC Rights for Zegerid Products to Schering-Plough
Next articlePatent Issued for Delivery of Recombinant AAV Vectors